BiotechTube
Home/Pipeline/AUTO8

AUTO8

Relapsed/Refractory Multiple Myeloma

Phase 1ActiveNCT03294954

Key Facts

Indication
Relapsed/Refractory Multiple Myeloma
Phase
Phase 1
Status
Active
Company
Autolus Therapeutics

About Autolus Therapeutics

Autolus Therapeutics is a UK-based biotech focused on developing advanced, programmed CAR T-cell therapies with the goal of delivering life-changing benefits to patients. Its most advanced asset, obecabtagene autoleucel (obe-cel), has demonstrated compelling clinical data in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) and is progressing through late-stage development. The company's strategy hinges on its proprietary technology platform to create differentiated products, vertical integration for manufacturing control, and expansion into solid tumors and autoimmune diseases to build a diversified pipeline.

View full company profile

Therapeutic Areas

OncologyAutoimmune Diseases

Other Relapsed/Refractory Multiple Myeloma Drugs

DrugCompanyPhase
Aplidin (plitidepsin)PharmaMarApproved (Conditional - AU)
TECVAYLI + DARZALEX FASPROjohnson-and-johnson-innovative-medicineApproved
LinvoseltamabRegeneronPhase 3
Blenrep (belantamab mafodotin)GSKPhase III
CAR T-Cell Therapy ProgramDr. Reddy's LaboratoriesDevelopment
HDP-101Heidelberg PharmaPhase I/IIa
inobrodib + Pd (InoPd)CellCentricPhase 1/2
CT053CARsgen TherapeuticsPhase Ib/II
CT059CARsgen TherapeuticsPhase I
P-BCMA-ALLO1Poseida TherapeuticsPhase 1
P-BCMA-101Poseida TherapeuticsPhase 1/2
ABBV-383AbbViePhase 1